We are currently collating sources of the latest research and peer reviewed publications about HSCT. We will add new articles as soon as we find them. Articles are displayed in descending order by publication date and you can filter the results using the drop down list below

Hematopoietic stem cell transplantation for multiple sclerosis: no inflammation, no response

Hematopoietic stem cell transplantation (HSCT) for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Is it CIDP?

Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis

Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis

Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials

Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

B cell depletion therapy does not resolve chronic active multiple sclerosis lesions

Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT

The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis

High-dose immunosuppressive therapy with autologous hematopoietic stem cells transplantation for multiple sclerosis: Current view

Stem Cell Therapy in Neuroimmunological Diseases and Its
Potential Neuroimmunological Complications

Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

ACTRIMS2022 – Immune System ‘Reset’ by Stem Cell Transplant (fully myeloablative)

Blood Stem Cell Transplant May Help Immune System Longer

HSCT versus cyclophosphamide for progression is no better

Autologous hematopoietic stem cell transplantation vs low-dose immunosuppression in secondary-progressive multiple sclerosis

Real‑world application of autologous hematopoietic stem cell
transplantation in 507 patients with multiple sclerosis

Relapse-independent multiple sclerosis progression under natalizumab

Splitting the Total Dose of Cyclophosphamide in Two Blocks Apart during the Conditioning of Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Results in Diminished Cardiotoxicity: Experience in 1,000 Patients

Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort

International stem cell tourism: a critical literature review and evidence-based recommendations

Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series

Getting Worse

AHSCT with Low-Intensity conditioning regimens in RRMS. Clinical outcomes and quality of life

Autologous hematopoietic stem cell transplantation with low-intensity conditioning regimens in relapsing remitting multiple sclerosis: clinical outcomes and quality of life

New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis

Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis

Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT)

Stem Cell Blood Transfusion Slows the Progression of Relapsing-Remitting Multiple Sclerosis

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

A general practitioner's guide to hematopoietic stem-cell transplantation

Position statement providing general information for patients and carers considering HSCT for severe autoimmune diseases

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs

Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases